caa a22 4500 469120754 CHVBK 20180323133138.0 cr unu---uuuuu 170328e19920601xx s 000 0 eng 10.1007/BF02245142 doi (NATIONALLICENCE)springer-10.1007/BF02245142 Long-term administration of m-chlorophenylpiperazine (mCPP) to rats induces changes in serotonin receptor binding, dopamine levels and locomotor activity without altering prolactin and corticosterone secretion [Elektronische Daten] [Jakob Ulrichsen, John Partilla, Elizabeth Dax] Meta-chlorophenylpiperazine (mCPP) is a serotonin (5-HT) agonist with antidepressant actions. In order to investigate the effects of chronic mCPP treatment the drug was administered to rats for 15 days (5 mg/kg twice daily). Controls were administered saline. Long-term mCPP treatment led to a 36% increase in [3H]8-hydroxy-2-(di-n-propylamino)tetralin ([3H]8-OH-DPAT) binding to 5-HT1a receptors in hippocampus and a 74% decrease in [3H]ketanserin binding to 5-HT2 receptors in cortex, while (-)[125I]iodocyanopindolol ([125I]CYP) binding to 5-HT1b receptors in hypothalamus and striatum was unchanged. In hypothalamus, chronic mCPP treatment decreased the levels of dopamine (DA) but not 5-HT. The usual suppression of locomotor activity induced by acute mCPP administration was less after long-term mCPP treatment. Brain and plasma levels of mCPP following an acute dose were not different between controls and rats previously administered mCPP, suggesting that altered rate of metabolism of the drug did not explain the tolerance to the mCPP-induced decrease in locomotor activity. mCPP-induced prolactin (PRL) and corticosterone release were not changed by previous long-term mCPP administration. Thus, chronic mCPP administration to rats induced alterations in density of 5-HT receptor subtypes, hypothalamic levels of DA and locomotor behavior. Springer-Verlag, 1992 Serotonin nationallicence m-Chlorophenylpiperazine nationallicence Receptors, 5-HT1a, 5-HT1b, 5-HT2 nationallicence Locomotor activity nationallicence Neurotransmitters nationallicence Prolactin nationallicence Corticosterone nationallicence Ulrichsen Jakob Neuroendocrinology/Immunology Laboratory, Addiction Research Center, National Institute on Drug Abuse, P.O. Box 5180, 21224, Baltimore, MD, USA aut Partilla John Neuroendocrinology/Immunology Laboratory, Addiction Research Center, National Institute on Drug Abuse, P.O. Box 5180, 21224, Baltimore, MD, USA aut Dax Elizabeth Neuroendocrinology/Immunology Laboratory, Addiction Research Center, National Institute on Drug Abuse, P.O. Box 5180, 21224, Baltimore, MD, USA aut Psychopharmacology Springer-Verlag 107/2-3(1992-06-01), 229-235 0033-3158 107:2-3<229 1992 107 213 https://doi.org/10.1007/BF02245142 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02245142 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Ulrichsen Jakob Neuroendocrinology/Immunology Laboratory, Addiction Research Center, National Institute on Drug Abuse, P.O. Box 5180, 21224, Baltimore, MD, USA aut NATIONALLICENCE 700 1- Partilla John Neuroendocrinology/Immunology Laboratory, Addiction Research Center, National Institute on Drug Abuse, P.O. Box 5180, 21224, Baltimore, MD, USA aut NATIONALLICENCE 700 1- Dax Elizabeth Neuroendocrinology/Immunology Laboratory, Addiction Research Center, National Institute on Drug Abuse, P.O. Box 5180, 21224, Baltimore, MD, USA aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 107/2-3(1992-06-01), 229-235 0033-3158 107:2-3<229 1992 107 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer